This analysis presents a path forward for the expansion of VBC to promote orphan drug development, expand access to pharmaceuticals, and improve patient safety and explores different contracting options and paths for organizations like CMS and integrated payer-provider networks.
Urvisha Jain, Srinidhi Polkampally, Arnav Ajay Jadav et al.· Value in Health· 0 citations
A mutation in the estrogen receptor alpha gene (ESR1m) following first-line treatment with endocrine therapy in hormone receptor-positive metastatic breast cancer occurs in nearly half of patients. Detection of this mutation prior to radiologic progression using circulating tumor DNA (ctDNA)-based monitoring is an emer...
Bridget M. Flavin, C. Tweed, J. Evans et al.· Journal of Managed Care & Sp...· 0 citations
Practical, experience-informed considerations are supplemented by an opinion-based consensus workflow model designed to provide clinicians with a flexible framework for implementing ctDNA-based ESR1m monitoring during first-line care for ER+, HER2– aBC.
Y. Abdou, Amber Cipriani, Trevor Feinstein et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.